Vera Therapeutics, Inc. (VERA) · Nov 5, 2026 · Earnings

Vera Therapeutics earnings beat as Trutakna launch clears early bar

Beat — Revenue $10.3M vs ~$3.42M consensus; EPS $(1.30) vs $(1.62) consensus

Vera Therapeutics’ Q3 earnings beat on early Trutakna sales, while final trial data and an FDA filing strengthen the drug’s approval path.

Vera is moving from clinical-stage biotech to commercial launch, with TRUTAKNA now its first marketed product after accelerated FDA approval in July 2026. Published expectations called for only about $3.42 million of Q3 revenue and a $1.62 per-share loss, while broader estimates expected roughly $24 million of TRUTAKNA revenue for all of 2026.

The launch started materially ahead of the low initial bar. Q3 net product revenue was $10.3 million versus no revenue a year earlier and about $3.42 million of published consensus, while the $1.30 per-share loss was also better than the roughly $1.62 consensus loss. The company also reported approximately 700 Patient Start Forms since launch, giving the commercial story an early proof point rather than just an approval headline.

MetricQ3 2026Q3 2025Consensus / comparator
Net product revenue (Financial Results)$10.3M$0~$3.42M
Net loss per share (Financial Results)$(1.30)$(1.26)$(1.62)
Net loss (Financial Results)$(93.7M)$(80.3M)
Selling, general and administrative (Financial Results)$61.4M$27.5M
Operating cash used, nine months (Financial Results)$(305.9M)$(171.1M)
ORIGIN 3 annualized eGFR slope (ORIGIN 3 results)-0.6Placebo: -5.6

The clinical evidence materially strengthens the commercial product’s foundation. Final ORIGIN 3 results showed kidney-function decline nearly stabilized relative to the placebo trajectory, with a 5.0 mL/min/1.73m²/year treatment difference and a reported 76% reduction in composite kidney-disease progression risk through two years. Vera said TRUTAKNA met all prespecified endpoints, and the data supported its November 3 submission for full FDA approval. 〔0〕

The trade-off is a much heavier commercial cash burn. Selling and administrative expense more than doubled as Vera built its launch organization, and operating cash use for the first nine months rose to $305.9 million from $171.1 million. The company still had $384.0 million in cash, equivalents and marketable securities at quarter-end and drew $75 million in late October, but the launch must convert early prescriptions into sustained revenue before the financial profile improves.

Bottom line: This is a clear earnings beat alongside unusually strong confirmatory clinical data, advancing Vera’s story from “approved launch candidate” to “early commercial product with a stronger full-approval case.” The launch is still young and cash-intensive, but the filing is meaningfully better than the standing expectation rather than merely on plan.

What to watch next

FDA full-approval decision expected in mid-2027

Original filing on SEC EDGAR

More Vera Therapeutics, Inc. news

Vera Therapeutics earnings beat as Trutakna launch clears early bar | VERA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.